cbdMD Overview
Latest ROE for cbdMD: -12.96% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-12.96%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
cbdMD (YCBD) currently reports a ROE of -12.96%. That is below the Consumer Discretionary sector average of 23.79%. Use the charts on this page to explore cbdMD's ROE history and peer comparisons.
cbdMD's ROE of -12.96% is lower than the Consumer Discretionary sector average of 23.79%. That is roughly 154.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but cbdMD's current -12.96% should be judged against Consumer Discretionary norms (sector average: 23.79%) and against YCBD's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -12.96%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Consumer Discretionary average is 23.79%. From there, open related valuation or income-statement pages for cbdMD, and consider following YCBD for alerts when major investors trade the stock.
cbdMD is classified in the Consumer Discretionary sector. On ROE, it currently shows -12.96% versus a sector average near 23.79%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Consumer Discretionary are usually more informative than comparing YCBD with unrelated industries.
